IL-17A identified as a potential driver of cancer in familial adenomatous polyposis
Familial adenomatous polyposis (FAP) is a hereditary disease which, in addition to a high risk of bowel cancer, also a greatly increased risk of duodenal cancer. At present, the only treatment available is close endoscopic monitoring with removal of the precursors, known as polyps, although this is also associated with an increased risk.
But there are no specific preventive therapies. Since the severity of the disease varies greatly even among carriers of the same gene mutation, the search is on for other factors that influence the development of the disease – and the local immune system is becoming the focus of attention.”
Dr. Benjamin Krämer, Co-Lead Author, Scientific Head of the Laboratory for Congenital Cellular Immunology, UKB
Neurotransmitter causes damage to the genetic material
The Bonn researchers have now discovered that certain cells of the innate immune system, known as type 3 innate lymphoid cells (ILC3), are present in significantly higher numbers in the duodenum of FAP patients. “We found an increased number of these cells in the mucosa, particularly in the vicinity of polyps and cancerous areas,” says co-lead author Dr. Robert Hüneburg, senior physician at the Medical Clinic I and the National Center for Hereditary Tumor Diseases at the UKB.
The Bonn research findings provide clues as to how these immune cells could contribute to the development of cancer: they produce a Neurotransmitter called interleukin-17A (IL-17A). “This messenger appears to stimulate intestinal cells to produce more harmful molecules known as reactive oxygen species, or ROS for short. High concentrations of these ROS can damage the genetic material in the cells,” says first author Dr. Kim Melanie Kaiser, who until recently conducted research as a doctoral student in the ImmunoSensation² Cluster of Excellence at the University of Bonn. Such damage to DNA, the carrier of genetic information, is a known factor that can drive the development of cancer.
“Our findings suggest that the increased number of interleukin-17A-producing ILC3 in the duodenum creates a local environment that favors the development of cancer in FAP patients,” says co-lead author Prof. Dr. Jacob Nattermann from the Laboratory for Innate Cellular Immunity, Deputy Director of Medical Clinic I and Senior Physician at the National Center for Hereditary Tumor Diseases at the UKB. He is also a member of the Cluster of Excellence ImmunoSensation² and the Transdisciplinary Research Area (TRA) “Life & Health” at the University of Bonn. “Targeting these immune cells or, in particular, blocking the messenger substance IL-17A directly in the duodenum could therefore represent a promising new approach to preventing duodenal cancer in people with FAP and offer an urgently needed therapeutic option in addition to pure endoscopic monitoring.”
Participating institutions and funding:
These results are based on a collaboration between research institutions from all over Germany. The study was conducted under the leadership of researchers from Medical Clinic I at the University Hospital Bonn (UKB), with the ImmunoSensation² Cluster of Excellence at the University of Bonn also playing a key role. Also involved were the German Center for Neurodegenerative Diseases (DZNE) in Bonn, the German Rheumatism Research Center (DRFZ), which is affiliated with the Charité University Hospital in Berlin and cooperated as part of the DFG Priority Program SPP 1937 “Innate Lymphoid Cells”, and the Ludwig-Maximilians-Universität (LMU) Munich, which participated in the context of the German Center for Infection Research (DZIF).
Kaiser, K. M., et al. (2025). IL-17A-producing NKp44(−) group 3 innate lymphoid cells accumulate in Familial Adenomatous Polyposis duodenal tissue. Nature Communications. doi.org/10.1038/s41467-025-58907-y.
